Apollo Hospitals Enterprise Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
APOLLOHOSP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty 100 and 3.2 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Apollo Hospitals reported strong full-year FY2026 results. On a consolidated basis, revenue grew 15.7% to Rs. 252,285 million from Rs. 217,940 million, driven by growth across all segments including healthcare services, retail health, and digital health/pharmacy distribution. Profit after tax surged 33.1% to Rs. 20,027 million from Rs. 15,051 million, significantly outperforming the prior year. Basic EPS improved to Rs. 135.04 from Rs. 100.56. The Board declared an interim dividend of Rs. 10 per share (already paid) and recommended a final dividend of Rs. 10 per share, subject to shareholder approval. Statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated financial statements. Notable corporate actions include a proposed merger of Apollo Hospitals North Limited (wholly owned subsidiary) into the Company, and a transaction for AHLL to divest stakes in two subsidiaries to Kids Clinic India Limited (Cloudnine) at an enterprise value of Rs. 15,500 million.
Apollo Hospitals delivered robust double-digit growth in both revenue and profitability for FY2026, with PAT growth exceeding 33% on consolidated basis. The clean audit opinion and dividend declarations are positive signals for shareholders. The proposed corporate restructuring and divestment transactions may drive long-term value but carry execution and regulatory risks.